- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Britain's largest pharmaceuticals company reports growth in its HIV medicines business as it submits a shingles vaccine for FDA approval.
The group's blood cancer drug Gleevec also holds up better than expected against generic competition.
Forward-looking purchasing managers' indices and earnings from beleaguered lender Deutsche Bank feature among the other release highlights.
For the week of October 24, investors await quarterly results from a slew of major companies, including Apple, along with the first estimate of third quarter GDP.